Haloperidol Successfully Treated a Severe Case of Cannabinoid Hyperemesis Syndrome
A patient with cannabinoid hyperemesis syndrome who did not respond to standard treatments found relief with haloperidol, suggesting a new treatment option for this difficult condition.
Quick Facts
What This Study Found
This case report documented a patient with cannabinoid hyperemesis syndrome (CHS), a condition characterized by severe cyclic vomiting, nausea, and abdominal pain in people who use cannabis chronically.
CHS is often unrecognized or misdiagnosed, leading to unnecessary medical workups and repeated hospitalizations. While long-term abstinence from cannabis is the definitive treatment, managing acute episodes has been challenging for clinicians.
In this case, haloperidol (an antipsychotic medication) successfully resolved the patient's symptoms when other conventional treatments had failed. The authors highlight haloperidol as a safe and effective acute treatment option for the unrelenting symptoms of CHS.
Key Numbers
Single patient case. The abstract does not specify the haloperidol dose used.
How They Did This
Single case report documenting the clinical presentation, failed conventional treatments, and successful response to haloperidol in a patient with cannabinoid hyperemesis syndrome.
Why This Research Matters
CHS is increasingly recognized as cannabis use has expanded, and emergency physicians need effective acute treatments. This case adds to growing evidence that haloperidol may be particularly effective for CHS, potentially because it blocks dopamine receptors involved in the vomiting pathway that traditional antiemetics do not adequately address.
The Bigger Picture
CHS represents one of the clearest adverse effects of chronic cannabis use. The emergence of haloperidol as a treatment option is notable because standard antiemetics often fail in CHS, and hot showers, while providing temporary relief, are not a practical long-term solution for acute episodes.
What This Study Doesn't Tell Us
Single case report provides the lowest level of clinical evidence. No control comparison or dosing protocol was established. The mechanism of action for haloperidol in CHS is not fully understood.
Questions This Raises
- ?Does haloperidol work for CHS through dopamine blockade, 5-HT2A antagonism, or another mechanism?
- ?Would a clinical trial confirm its effectiveness across a larger patient population?
- ?Is there an optimal dosing protocol for haloperidol in CHS?
Trust & Context
- Key Stat:
- Haloperidol resolved CHS symptoms when standard antiemetics failed
- Evidence Grade:
- Single case report, providing the lowest tier of clinical evidence. Preliminary but adds to accumulating reports of haloperidol efficacy in CHS.
- Study Age:
- Published in 2017.
- Original Title:
- Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?
- Published In:
- BMJ case reports, 2017 (2017)
- Authors:
- Inayat, Faisal(2), Virk, Hafeez Ul Hassan, Ullah, Waqas, Hussain, Qulsoom
- Database ID:
- RTHC-01410
Evidence Hierarchy
Describes what happened to one person or a small group.
What do these levels mean? →Frequently Asked Questions
What is cannabinoid hyperemesis syndrome?
CHS is a condition in chronic cannabis users marked by severe nausea, cyclic vomiting, and abdominal pain. It is often misdiagnosed, leading to unnecessary tests and hospitalizations. The definitive treatment is stopping cannabis use.
How is CHS treated acutely?
Long-term, the only cure is cannabis abstinence. For acute episodes, standard antiemetics often fail. This case report and others suggest haloperidol may be effective when conventional treatments do not work.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01410APA
Inayat, Faisal; Virk, Hafeez Ul Hassan; Ullah, Waqas; Hussain, Qulsoom. (2017). Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?. BMJ case reports, 2017. https://doi.org/10.1136/bcr-2016-218239
MLA
Inayat, Faisal, et al. "Is haloperidol the wonder drug for cannabinoid hyperemesis syndrome?." BMJ case reports, 2017. https://doi.org/10.1136/bcr-2016-218239
RethinkTHC
RethinkTHC Research Database. "Is haloperidol the wonder drug for cannabinoid hyperemesis s..." RTHC-01410. Retrieved from https://rethinkthc.com/research/inayat-2017-is-haloperidol-the-wonder
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.